Alteplase (r-TPA) vs streptokinase. - Wikidata - wikimedia - TriplyDB

Alteplase (r-TPA) vs streptokinase.

Alteplase (r-TPA) vs streptokinase.

http://www.wikidata.org/entity/Q40839524

about

Elongated plant virus-based nanoparticles for enhanced delivery of thrombolytic therapies.

P2860

Q40053619-2E5E673F-269C-475E-9ED1-60A2BFF57442

P2860

Alteplase (r-TPA) vs streptokinase.

http://www.wikidata.org/entity/Q40839524

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Alteplase (r-TPA) vs streptokinase.

@en

type

label

Alteplase (r-TPA) vs streptokinase.

@en

prefLabel

Alteplase (r-TPA) vs streptokinase.

@en

P1433

Q40839524-CF09EAEB-B726-4616-AC38-D6BB6849EF11

P1476

Q40839524-92EDE08C-39EB-41F8-99B1-C920794C4559

P2093

Q40839524-3379620A-B57D-4A2E-B01A-CAA9718E5D4A

P2860

Q40839524-29914910-5F3E-4F8D-86DE-E9AC685C4F5F

Q40839524-332CB75F-9270-4651-890F-F3EA48C68AAF

Q40839524-A06A0DCC-6F2D-468D-AD18-6BD75BD3FE63

Q40839524-C29A4138-8EF9-46DC-8B4F-A8675E51F363

Q40839524-D3D7AD19-CE5F-481E-9620-C39235CC7ADC

Q40839524-F45CB24F-8642-4E2A-92C8-834E338B33BB

P304

Q40839524-0A2A9C3D-3D49-485E-9CC1-8A8DBDDA04A6

P31

Q40839524-4B9692A3-8651-4499-BF2E-A4841EBF6F9D

P356

Q40839524-1EDFE8A0-FCB4-4E09-BA28-B6BC086C7138

P433

Q40839524-79A3C9AD-A431-4169-A96C-24CCEA63AC6A

P478

Q40839524-607CD456-148B-4250-BCA6-6AA232A14DAD

P577

Q40839524-3DC29479-64C7-4262-BDB4-8450A842844D

P698

Q40839524-C38C8161-B64B-4C8C-B9C8-F7A3CBE35A2E

P356

J.1445-5994.1998.TB02102.X

P1433

Australian and New Zealand journal of medicine

P1476

Alteplase (r-TPA) vs streptokinase.

@en

P2093

Hunt D

http://www.w3.org/2001/XMLSchema#string

P2860

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.

Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.

Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG

Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy.

Efficacy of Streptokinase, but Not Tissue-Type Plasminogen Activator, in Achieving 90-Minute Patency After Thrombolysis for Acute Myocardial Infarction Decreases With Time to Treatment

P304

514-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1445-5994.1998.TB02102.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

1998-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9777131

http://www.w3.org/2001/XMLSchema#string